CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

被引：31

作者：

Vuilleumier N. ^{[1
]}

Rossier M.F. ^{[1
,5
]}

Chiappe A. ^{[1
]}

Degoumois F. ^{[1
]}

Dayer P. ^{[2
]}

Mermillod B. ^{[3
]}

Nicod L. ^{[4
]}

Desmeules J. ^{[2
]}

Hochstrasser D. ^{[1
]}

机构：

[1] Central Clinical Chemistry Laboratory, Department of Clinical Pathology, Geneva University Hospital, 1211 Geneva 14

[2] Clinical Pharmacology and Toxicology, Geneva University Hospital

[3] Service of Medical Informatics, Geneva University Hospital

[4] Service of Pneumology, Geneva University Hospital

[5] Service of Endocrinology and Diabetology, Geneva University Hospital

来源：

European Journal of Clinical Pharmacology | 2006年 / 62卷 / 6期

关键词：

Cosmopolite population; CYP2E1; Taq1; polymorphism; Isoniazid-induced hepatitis; NAT2; genotype; Negative predictive value; Positive predictive value;

D O I：

10.1007/s00228-006-0111-5

中图分类号：

学科分类号：

摘要：

Objective: To determine whether pharmacogenetic tests such as N-acetyltransferase 2 (NAT2) and cytochrome P450 2E1 (CYP2E1) genotyping are useful in identifying patients prone to antituberculosis drug-induced hepatotoxicity in a cosmopolite population. Methods: In a prospective study we genotyped 89 patients treated with isoniazid (INH) for latent tuberculosis. INH-induced hepatitis (INH-H) or elevated liver enzymes including hepatitis (INH-ELE) was diagnosed based on the clinical diagnostic scale (CDS) designed for routine clinical practice. NAT2 genotypes were assessed by fluorescence resonance energy transfer probe after PCR analysis, and CYP2E1 genotypes were determined by PCR with restriction fragment length polymorphism analysis. Results: Twenty-six patients (29%) had INH-ELE, while eight (9%) presented with INH-H leading to INH treatment interruption. We report no significant influence of NAT2 polymorphism, but we did find a significant association between the CYP2E1 *1A/*1A genotype and INH-ELE (OR: 3.4; 95% CI:1.1-12; p=0.02) and a non significant trend for INH-H (OR: 5.9; 95% CI: 0.69-270; p=0.13) compared with other CYP2E1 genotypes. This test for predicting INH-ELE had a positive predictive value (PPV) of 39% (95% CI: 26-54%) and a negative predictive value (NPV) of 84% (95% CI: 69-94%). Conclusion: The genotyping of CYP2E1 polymorphisms may be a useful predictive tool in the common setting of a highly heterogeneous population for predicting isoniazid-induced hepatic toxicity. Larger prospective randomized trials are needed to confirm these results. © Springer-Verlag 2006.

引用

页码：423 / 429

页数：6

共 43 条

[1]

Dye C., Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence and mortality by country. WHO Global Surveillance and Monitoring Project, JAMA, 282, pp. 677-686, (1999)

[2]

Durant F., Jebrak G., Pessayre D., Fournier M., Bernau J., Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status, Drug Saf, 16, pp. 394-405, (1996)

[3]

Martinjak-Dvorsek I., Gorjup V., Horvat M., Noc M., Acute isoniazid neurotoxicity during preventive therapy, Crit Care Med, 28, pp. 567-568, (2000)

[4]

Watkins R.C., Hambrick E.L., Benjamin G., Chavda S.N., Isoniazid toxicity presenting as seizures and metabolic acidosis, J Natl Med Assoc, 82, pp. 57-64, (1990)

[5]

Schaberg T., Rebhan K., Lode H., Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis, Eur Respir J, 9, pp. 2026-2030, (1996)

[6]

Morant J., Ruppaner H., Compendium Suisse des Médicaments, 24th Edn., (2003)

[7]

Yee D., Valiquette C., Pelletier M., Parisien I., Rocher I., Menzies D., Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis, Am J Respir Crit Care Med, 167, pp. 1472-1477, (2003)

[8]

Steele M.A., Burk R.F., DesPrez R.M., Toxic hepatitis with isoniazid and rifampin a meta-analysis, Chest, 99, pp. 465-471, (1991)

[9]

Saram G.R., Imanuel C., Kailasam S., Narayana A.S.L., Venkatesan P., Rifampin -induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regiments containing isoniazid and rifampin, Am Rev Dis, 133, pp. 1072-1075, (1986)

[10]

Mitchell J.R., Thorgeisson U.P., Black M., Et al., Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydralazine metabolites, Clin Pharmacol Ther, 18, pp. 70-79, (1975)

← 1 2 3 4 5 →